The 2007 and 2008 guidance is in line with expectations. And the stock is back down after a pretty big move.

We've seen a lot of pharmaceutical companies move out of their non-core businesses. It's a pretty good move.

Today's drop is because of missed earnings expectations for the fourth quarter and also that the guidance for the 2006 production was slightly underwhelming.

Tiffany reported earnings above our expectations ... first-quarter guidance appears light.

The guidance is going up and the numbers were above expectations across the board, particularly on the integration of Allied. It's pretty good news all round.

I am open to the guidance of synchronicity, and do not let expectations hinder my path.